Hideki Fujii

Hideki Fujii

Auto-generated profile, based on publicly available information

Hideki Fujii

The University of Tokyo

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2009 in Cancer Science
Verified
Journal Article
Open access
PDF file
KKKoji Kono
Koji Kono
YMYoshiki Mizukami
Yoshiki Mizukami
YDYataro Daigo
Yataro Daigo
ATAtsushi Takano
Atsushi Takano
KMKen Masuda
Ken Masuda
HFHideki Fujii
Hideki Fujii
We previously identified three novel HLA‐A24‐restricted epitope peptides, which were derived from three cancer‐testis antigens, TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin‐like growth factor (IGF)‐II mRNA binding protein 3 (IMP‐3), as targets for cancer vaccination against esophageal squamous cell carcinoma (ESCC). To examine the safety, immunogenicity, and antitumor effect of vaccine treatment using a combination of these three peptides, 10 HLA‐A2402‐positive advanced ESCC patients who failed to standard therapy were enrolled in a phase I clinical trial. Each of the three peptides (1 mg each) was intradermally administered with 1 mL of incomplete Freund's adjuvant to the neck in three separate regions weekly for 5 weeks. The cancer vaccination therapy was well tolerated without any treatment‐associated adverse events of grade 3 or 4. The TTK‐, LY6K‐, and/or IMP‐3‐specific T‐cell immune responses were observed by enzyme‐linked immunospot assay in peripheral blood lymphocytes obtained from nine of the 10 ESCC patients after their vaccination. The median survival time after the vaccination was 6.6 months. The vaccination could induce good clinical responses in 50% of the 10 patients. One patient experienced a complete response in hepatic metastasis lasting 7 months, one showed objective responses in all lung metastasis lesions, and three patients revealed a stable disease condition for at least 2.5 months. The cancer vaccine therapy using these three peptides demonstrated satisfactory safety and good immunogenicity as well as promising disease control rate, and therefore warrants further clinical studies. (Cancer Sci 2009)

14 September 1999 in Journal of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
PDF file
HFHideki Fujii
Hideki Fujii
YYYang Yang
Yang Yang
RTRuifang Tang
Ruifang Tang
KKKazuyosi Kunitomo
Kazuyosi Kunitomo
JIJun Itakura
Jun Itakura
YMYoshiro Matsumoto
Yoshiro Matsumoto

1 June 2006 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KKKoji Kono
Koji Kono
ATAkihiro Takahashi
Akihiro Takahashi
HSHidemitsu Sugai
Hidemitsu Sugai
HIHidehiko Iizuka
Hidehiko Iizuka
HFHideki Fujii
Hideki Fujii

1 November 1993 in Surgery Today
Verified
Journal Article
Closed access
PDF file
MYMasayuki Yamamoto
Masayuki Yamamoto
MMMasanori Matsuda
Masanori Matsuda
YIYuji Iimuro
Yuji Iimuro
HFHideki Fujii
Hideki Fujii
KNKaoru Nagahori
Kaoru Nagahori
TATakao Ainota
Takao Ainota

1 January 2022 in Journal of Information Processing
Verified
Journal Article
Open access
PDF file
Shuo WangShuo Wang
Shuo Wang
HFHideki Fujii
Hideki Fujii
SYShinobu Yoshimura
Shinobu Yoshimura
Reliable driving intention inference is an essential issue in the mixed automation traffic system. To improve traffic safety and efficiency, this study develops an accurate and efficient driving intention inference framework named FES-XGB, which is short for Feature Extraction and Selection based eXtreme Gradient Boosting (XGBoost) algorithm. In contrast with conventional approaches, which only consider motion information of the subject and neighboring vehicles, this study includes a new kind of decision variables into driving intention inference for the first time, i.e., the local and global traffic environment information assumed to be obtained from vehicle to vehicle (V2V) and vehicle to infrastructure (V2I) technology. The high-precision NGSim trajectory dataset is employed to learn the relationship between traffic environment information and driving intentions and evaluate the proposed framework. According to the experiment results, by taking the environment information as additional input, the accuracy of the conventional XGBoost model can increase from 89.42% to 92.86%, indicating the environment information has a close relationship with the driving intention. By employing the proposed FES-XGB framework, the accuracy can be further increased to 94.09%, while the training and online inference cost can be reduced by 94.03% and 65.25% respectively. With the traffic environment information as additional input, the proposed FES-XGB framework can be integrated into advanced driver-assistance systems (ADAS) for a safer and more efficient traffic system.

10 May 2022 in JGH Open
Verified
Journal Article
Open access
HFHideki Fujii
Hideki Fujii
HKHiroyuki Kimura
Hiroyuki Kimura
CHChitomi Hasebe
Chitomi Hasebe
TATakehiro Akahane
Takehiro Akahane
TSTakashi Satou
Takashi Satou
NINamiki Izumi
Namiki Izumi
Background and Aim: This study aimed to evaluate the long‐term clinical course of patients achieving a sustained virologic response (SVR) with daclatasvir plus asunaprevir (DCV/ASV) therapy.Methods: A total of 911 patients who achieved SVR with DCV/ASV were assessed. To evaluate pretreatment factors contributing to hepatocellular carcinoma (HCC) after SVR, univariate and multivariate analyses were performed in all patients, in those with preexisting HCC, and in those without preexisting HCC. We selected a low‐risk group of HCC cases after SVR. Finally, we evaluated liver function after achieving SVR.Results: In multivariable analyses, male sex, older age, patients with a history of HCC treatment, excess alcohol use, lower albumin, and low platelet count remained significant in the overall group; male sex and low albumin remained significant in patients with a history of HCC treatment; and male sex, older age, excess alcohol use, low platelet count, high alpha‐fetoprotein (AFP), and high des‐γ‐carboxy prothrombin (DCP) remained significant in those without a history of HCC treatment. Patients who had not received treatment for HCC, females, those under 70 years of age, and those with platelet count ≥13 (×104/μL), AFP <6 ng/mL, and DCP <23 mAU/mL were at low risk of HCC. The process of liver function improvement was different according to the factors.Conclusions: The incidence rate of HCC, risk factors associated with HCC, group with very low risk of developing HCC, and the clinical course in a real‐world long‐term study were evaluated.